

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>CR Group L.P.</u> <hr/> (Last) (First) (Middle) 1000 MAIN STREET, SUITE 2500 <hr/> (Street) HOUSTON TX 77002 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>T2 Biosystems, Inc. [ TTOO ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
	Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
Common Stock	02/14/2024		C		335,947	A	(I)	335,947	I	By CRG Partners III (Cayman) Lev AIV I L.P. <sup>(2)</sup>	
Common Stock	02/14/2024		C		488,273	A	(I)	488,273	I	By: CRG Partners III Parallel Fund B LP <sup>(2)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(I)	02/14/2024		C		33,594.71		07/03/2023	(3)	Common Stock	335,947	\$0	0	I	By: CRG Partners III (Cayman) Lev AIV I L.P. <sup>(2)</sup>
Series B Preferred Stock	(I)	02/14/2024		C		48,827.3		07/03/2023	(3)	Common Stock	488,273	\$0	10,875.25	I	By: CRG Partners III Parallel Fund B LP <sup>(2)</sup>

1. Name and Address of Reporting Person\*  
CR Group L.P.  


---

 (Last) (First) (Middle)  
 1000 MAIN STREET, SUITE 2500  


---

 (Street)  
 HOUSTON TX 77002  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
CRG Partners III (Cayman) Lev AIV I L.P.  


---

 (Last) (First) (Middle)  
 1000 MAIN STREET, SUITE 2500

(Street)	HOUSTON	TX	77022
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
<a href="#">CRG Partners III - Parallel Fund B (Cayman) L.P.</a>			
(Last)	(First)	(Middle)	
1000 MAIN STREET, SUITE 2500			
(Street)	HOUSTON	TX	77002
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
<a href="#">CRG Partners III L.P.</a>			
(Last)	(First)	(Middle)	
1000 MAIN STREET, SUITE 2500			
(Street)	HOUSTON	TX	77002
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
<a href="#">CRG Partners III - Parallel Fund (A) L.P.</a>			
(Last)	(First)	(Middle)	
1000 MAIN STREET, SUITE 2500			
(Street)	HOUSTON	TX	77002
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
<a href="#">CRG Partners III (Cayman) Unlev AIV I L.P.</a>			
(Last)	(First)	(Middle)	
1000 MAIN STREET, SUITE 2500			
(Street)	HOUSTON	TX	77002
(City)	(State)	(Zip)	

**Explanation of Responses:**

- Each share of Series B Preferred Stock converted into 10 shares of Common Stock for no additional consideration.
- CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
- The preferred stock has no expiration date.

/s/ Nathan D. Hukill, authorized signatory for CR Group LP, CRG Partners III LP, CRG Partners III Parallel Fund (A) LP, CRG Partners III Parallel Fund B LP, CRG Partners III (Cayman) Unlev AIV I LP, CRG Partners III (Cayman) Lev AIV I LP

02/16/2024

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.